FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $672,000 | -24.5% | 29,993 | +30.7% | 0.02% | -30.4% |
| Q1 2022 | $890,000 | -59.0% | 22,943 | -8.2% | 0.02% | -25.8% |
| Q2 2021 | $2,170,000 | -45.7% | 25,000 | -48.4% | 0.03% | -38.0% |
| Q1 2021 | $3,993,000 | -44.8% | 48,431 | -39.1% | 0.05% | -36.7% |
| Q4 2020 | $7,234,000 | +261.9% | 79,560 | +59.1% | 0.08% | +107.9% |
| Q3 2020 | $1,999,000 | +16.5% | 50,000 | 0.0% | 0.04% | -17.4% |
| Q2 2020 | $1,716,000 | +220.7% | 50,000 | +107.5% | 0.05% | +109.1% |
| Q1 2020 | $535,000 | – | 24,100 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |